Esperion Therapeutics, Inc. (ESPR) Stock Score, Valuation & Financial Research
Esperion Therapeutics, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 26/100.
Quick answer for ESPR
Esperion Therapeutics, Inc. currently has a Wall Street Score of 26/100. The stored market price is $3.18. Its financial score is 30/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What Esperion Therapeutics, Inc. does
Esperion Therapeutics, Inc. operates as a pharmaceutical firm, concentrating on the development and commercialization of treatments for individuals with high levels of low-density lipoprotein (LDL) cholesterol. The company's flagship pharmaceutical products are NEXLETOL (bempedoic acid) and NEXLIZET (a tablet combining bempedoic acid and ezetimibe), prescribed for managing conditions such as atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. In addition, Esperion maintains a licensing and collaborative partnership with Daiichi Sankyo Europe GmbH, alongside an agreement with Serometrix to acquire rights to an oral, small molecule PCSK9 inhibitor program. Established in 2008, the company's corporate offices are situated in Ann Arbor, Michigan.
ESPR financial snapshot
- Wall Street Score:
- 26/100
- Current price:
- $3.18
- Market capitalization:
- $661.1M
- Revenue:
- $418.2M
- Net income:
- $-7.4M
- Free cash flow:
- $-13.1M
- Cash:
- $156.2M
- Total debt:
- $543.8M
- EPS:
- -0.02
- Financial score:
- 30/100
- Valuation score:
- 0/100
- Revenue score:
- 30/100
What stands out
- Reported year-over-year revenue growth is +0.0%.
- Free cash flow is $-13.1M, showing cash burn in the current stored period.
- The balance sheet shows $156.2M of cash versus $543.8M of total debt, so leverage deserves attention.
- The current research record carries a severe debt stress warning, which should be reviewed alongside the score.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 30/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-07.
How to research ESPR
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.